Geron nearly doubles in premarket trading on imetelstat data Geron ( GERN ) shareholders get great news for imetelstat in myelofibrosis. Overall response rate: 44%. CRs: 4 PRs: 1 From the research abstract: "The observed morphologic and molecular remissions confirm selective anti-clonal activity, which has thus far eluded other drugs in MF, including JAK inhibitors. The association between response and spliceosome mutations suggests a broader application ...
Nov. 7, 2013 - Seeking Alpha